BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| EMILY FELDER | — |
| STEPHEN HOLLAND | — |
| ZACHARY PFISTER | — |
| ADAM STEINMETZ | — |
| DEEMA TARAZI | — |
| ANDREW USYK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.